Clinical

This study shows little evidence of harms or increased health care utilization for people receiving negative (normal) results of expanded carrier screening through genome sequencing.

Using a systems biology approach, the researchers discovered 64 genes shared between non-alcoholic fatty liver disease (NAFLD) and hypertension, considered to be core genes for the 2 conditions.

In a recently published review, authors assessed the relationship between poor bone health and type 1 diabetes (T1D) and outlined potential mechanisms that may account for the association.

Chemotherapy is standard care for pediatric acute lymphoblastic leukemia (ALL), but new research shows thiopurines can cause mutations that result in relapse.

New research published in JAMA Network Open highlights one potential cause of migraine.

Camillo Ricordi, MD, FNAI, outlines the current status of islet transplantation for patients with type 1 diabetes in the United States.

Regular use of selective serotonin reuptake inhibitors or tricyclic or tetracyclic antidepressants was associated with a reduced risk of all-cause mortality in patients with diabetes.

Researchers were able to use a next-generation sequencing assay to not only monitor minimal residual disease (MRD), but also to confirm diagnosis of cutaneous T-cell lymphoma, which can present as more benign conditions early on.

A report reviews the case of a patient with stage IV melanoma who, while having several issues with treatment toxicity, was later free of disease following treatment with BRAF and MEK inhibitors.

Survey data found that better diagnosis and treatment methods are needed among patients with chronic cough in Japan due to the prevalent nature of the condition.

Patient-reported outcome measures may have a small impact on predicting which patients with cirrhosis will be readmitted to the hospital.

Results of a cross-sectional study point to a potential link between iron intake and migraine that may be dependent on age.

The latest news in rheumatology includes the need for robust vaccinations in juvenile idiopathic arthritis; new findings about rheumatoid arthritis (RA) and type 2 diabetes; and quality of life in systemic lupus erythematosus.

In an interim analyses of the phase 3 SEQUOIA trial, zanubrutinib had superior progression-free survival compared with bendamustine plus rituximab in patients with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL).

One diagnosis challenge is that there is no specific biomarker, either for autoimmune hepatitis (AIH) or metabolic-associated fatty liver disease (MAFLD), either alone or if they exist concurrently.

William "Andy" Nish, MD, an allergist and immunologist at Northeast Georgia Physicians Group, discusses the factors that influence whether patients with asthma should be prescribed a biologic therapy.

A newly released internal CDC report shows the agency's communication struggles and its challenges in combatting the virulent delta variant, acknowledges the need for universal masking, and illustrates the effectiveness of vaccines in preventing more severe illness and death in those who are inoculated.

A new CMS rule increases reimbursement for providers; coffee is linked to decreased risk of arrhythmia; the Johnson & Johnson COVID-19 vaccine’s shelf life is extended.

A new report is issuing a call to action to develop a global strategy to address the growing issue of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

The designation means that pharmacists can switch patients to the less-expensive version of insulin without seeking approval from the clinician.

Review findings outline the gut microbiome's potential impact on immunotherapy responses.

In the June Matters in Managed Care webinar, experts from Blue Cross and Blue Shield of North Carolina, Duke-Margolis Center for Health Policy, UNC Center for the Business of Health, and WakeMed discussed how they are working together to address some of the state’s unique primary care needs.

In the June Matters in Managed Care webinar, experts from Blue Cross and Blue Shield of North Carolina, Duke-Margolis Center for Health Policy, UNC Center for the Business of Health, and WakeMed discussed how they are working together to address some of the state’s unique primary care needs.

In the June Matters in Managed Care webinar, experts from Blue Cross and Blue Shield of North Carolina, Duke-Margolis Center for Health Policy, UNC Center for the Business of Health, and WakeMed discussed how they are working together to address some of the state’s unique primary care needs.

In the June Matters in Managed Care webinar, experts from Blue Cross and Blue Shield of North Carolina, Duke-Margolis Center for Health Policy, UNC Center for the Business of Health, and WakeMed discussed how they are working together to address some of the state’s unique primary care needs.

In the June Matters in Managed Care webinar, experts from Blue Cross and Blue Shield of North Carolina, Duke-Margolis Center for Health Policy, UNC Center for the Business of Health, and WakeMed discussed how they are working together to address some of the state’s unique primary care needs.

In the June Matters in Managed Care webinar, experts from Blue Cross and Blue Shield of North Carolina, Duke-Margolis Center for Health Policy, UNC Center for the Business of Health, and WakeMed discussed how they are working together to address some of the state’s unique primary care needs.

In the June Matters in Managed Care webinar, experts from Blue Cross and Blue Shield of North Carolina, Duke-Margolis Center for Health Policy, UNC Center for the Business of Health, and WakeMed discussed how they are working together to address some of the state’s unique primary care needs.

In the June Matters in Managed Care webinar, experts from Blue Cross and Blue Shield of North Carolina, Duke-Margolis Center for Health Policy, UNC Center for the Business of Health, and WakeMed discussed how they are working together to address some of the state’s unique primary care needs.

About 4 in 10 patients with chronic kidney disease will have “early rapid decline,” a trajectory more likely if the patient also has diabetes.